Table 3.

Median change in bone turnover markers from baseline to study week 13

	Zoledronic acid		Denosumab		p value
	Patients	Median absolute change (%, IQR)	Patients	Median absolute change (%, IQR)
uNTx/CR (nmol/mmol)	719	−28·4 (−69%, −83 to −43)	738	−40·3 (−84%, −92 to −66)	p<0·0001
Bone-specific alkaline phosphatase (µg/L)	739	−4·8 (−27%, −47 to 16)	755	−7·9 (−35%, −54 to −3)	p<0·0001

Data are presented for patients who had assessments at both baseline and week 13. uNTx/Cr=urinary N-telopeptide adjusted for creatinine.